{
    "clinical_study": {
        "@rank": "79187", 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration\n      study. Randomization will be stratified according to the patient's baseline serum sodium\n      concentration (137-144 and <137 mmol/L). The dose of study drug will be increased to the\n      next level on Day 15, and the total duration of the double-blind treatment period is 120\n      days."
        }, 
        "brief_title": "Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).", 
        "completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Men or women with chronic heart failure (NYHA Class IIIB and IV).\n\n          -  Women must be post-menopausal or surgically sterilized; they cannot be pregnant or\n             nursing.\n\n          -  Age 21 to 80 years.\n\n          -  Chronic heart failure of at least 3 months duration. For 2 months prior to screening,\n             patients must have had symptoms at rest or on minimal exertion for more than 50% of\n             the time. For 2 weeks prior to screening, patients must have had symptoms at rest or\n             on minimal exertion for more than 90% of the time.\n\n          -  Patients must be receiving a diuretic and an ACE inhibitor (or an angiotensin II\n             receptor antagonist) for the treatment of heart failure.\n\n          -  Patients may be receiving digoxin, a beta-blocker or spironolactone"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "338", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 29, 2002", 
        "id_info": {
            "nct_id": "NCT00032747", 
            "org_study_id": "DFI4510", 
            "secondary_id": "SR121463B"
        }, 
        "intervention": {
            "intervention_name": "Vasopressin V2 Receptor Antagonist", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vasopressins", 
                "Arginine Vasopressin"
            ]
        }, 
        "keyword": [
            "Chronic Heart Failure", 
            "Heart Disease"
        ], 
        "lastchanged_date": "June 16, 2008", 
        "link": [
            {
                "url": "http://www.centerwatch.com"
            }, 
            {
                "url": "http://www.sanofi-aventis.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242-1081"
                    }, 
                    "name": "University of Iowa Hospital and Clinics"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lincoln", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68510"
                    }, 
                    "name": "Brian LGH Heart Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45219"
                    }, 
                    "name": "The Lindner Clinical Trial Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "MUSC/Division Cardiology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Laval", 
                        "country": "Canada"
                    }, 
                    "name": "Sanofi-aventis Administrative Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guildford Surrey", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Sanofi-aventis Administrative Office"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "United Kingdom"
            ]
        }, 
        "official_title": "A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Effects of Vasopressin V2 Receptor Antagonist on Clinical Improvement in Patients With Severe Chronic Heart Failure", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "ICD CSD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": {
            "measure": "Clinical status at day 120."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00032747"
        }, 
        "responsible_party": {
            "name_title": "ICD Study Director", 
            "organization": "sanofi-aventis"
        }, 
        "secondary_outcome": {
            "measure": "NYHA functional class, left ventricular ejection fraction, global assessment,serum sodium concentration."
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2008"
    }, 
    "geocoordinates": {
        "Brian LGH Heart Institute": "40.807 -96.682", 
        "Emory University": "33.749 -84.388", 
        "MUSC/Division Cardiology": "32.777 -79.931", 
        "Sanofi-aventis Administrative Office": "51.236 -0.57", 
        "The Lindner Clinical Trial Center": "39.103 -84.512", 
        "University of Alabama at Birmingham": "33.521 -86.802", 
        "University of Iowa Hospital and Clinics": "41.661 -91.53", 
        "University of Maryland School of Medicine": "39.29 -76.612"
    }
}